Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2′-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 6, 2003, Pages 1107-1115

  Oscarsson, Karin ^a   Lahmann, Martina ^a   Lindberg, Jimmy ^b   Kangasmetsä, Jussi ^c   Unge, Torsten ^b   Oscarson, Stefan ^a   Hallberg, Anders ^b   Samuelsson, Bertil ^a,c  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; INHIBITOR PROTEIN; N1 (2 HYDROXY 2,3 DIHYDROXY 1H INDENYL) N6 (2 ALLYLOXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1 (2 HYDROXY 2,3 DIHYDROXY 1H INDENYL) N6 (2 ETHOXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1 (2 HYDROXY 2,3 DIHYDROXY 1H INDENYL) N6 (2 HYDROXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1 (2 HYDROXY 2,3 DIHYDROXY 1H INDENYL) N6 (2 METHOXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1 (2 HYDROXY 2,3 DIHYDROXY 1H INDENYL) N6 [2 (1' HYDROXY 2' METHYL)PROPYLTETRAHYDROFURAN 4 YL] 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1 (2 HYDROXY 2,3 DIHYDROXY 1H INDENYL) N6 [2 (1' HYDROXY)ETHYLTETRAHYDROFURAN 4 YL] 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(2 ALLYLOXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(2 ETHOXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(2 HYDROXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS(2 METHOXYMETHYLTETRAHYDROFURAN 4 YL) 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS[2 (1' HYDROXY 2' METHYL)PROPYLTETRAHYDROFURAN 4 YL] 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; N1,N6 BIS[2 (1' HYDROXY)ETHYLTETRAHYDROFURAN 4 YL] 2,5 DIBENZYLOXY 3,4 O DIHYDROXYHEXANEDIAMIDE; PROTEINASE INHIBITOR; TETRAHYDROFURAN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BINDING; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FURANS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037333331     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00535-7     Document Type: Article

References (37)

1. Gallo R.C., Sarin P.S., Gelmann E.P., Robert-Guroff M., Richardson E., Kalyanaraman V.S., Mann D., Sidhu G.D., Stahl R.E., Zolla-Pazner S., Leibowitch J., Popovic M. Science. 220:1983;865.
2. Barré-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axlier-Blin C., Vézinet-Brun F., Rouzioux C., Rozenbaum W., Montagnier L. Science. 220:1983;868.
3. McQuade T.J., Tomasselli A.G., Liu L., Karacostas V., Moss B., Sawyer T.K., Heinrikson R.L., Tarpley W.G. Science. 247:1990;454.
4. Seelmeier S., Schmidt H., Turk V., von der Helm K. Proc. Natl. Acad. Sci. U.S.A. 85:1988;6612.
5. Peng C., Ho B.K., Chang T.W., Chang N.T. J. Virol. 63:1989;2550.
6. Pearl L.H., Taylor W.R. Nature. 329:1987;351.
7. Huff J.R. J. Med. Chem. 34:1991;2305.
8. Kempf D.J., Sham H.L. Curr. Pharm. Design. 2:1996;225.
9. Mills J.S. Antiviral Chem. Chemoth. 7:1996;281.
10. Roberts N.A., Martin J.A., Kinchington D., Broadhurst A.V., Craig J.C., Duncan I.B., Galpin S.A., Handa B.K., Kay J., Kröhn A., Lambert R.W., Merrett J.H., Mills J.S., Parkes K.E.B., Redshaw S., Ritchie A.J., Taylor D.L., Thomas G.J., Machin P.J. Science. 248:1990;358.
11. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.-P., Wideburg N.E., Saldivar A., Ruiz L., Kati W.M., Sham H.L., Robins T., Stewart K.D., Hsu A., Plattner J.J., Leonard J.M., Norbeck D.W. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2484.
12. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., Sardana V.V., Schlabach A.J., Graham P.I., Condra J.H., Gotlib L., Holloway M.K., Lin J., Chen I.-W., Vastag K., Ostovic D., Anderson P.S., Emini E.A., Huff J.R. Proc. Natl. Acad. Sci. U.S.A. 91:1994;4096.
13. Dorsey B.D., Levin R.B., McDaniel S.L., Vacca J.P., Guare J.P., Darke P.L., Zugay J.A., Emini E.A., Schleif W.A., Quintero J.C., Lin J.H., Chen I.-W., Holloway M.K., Fitzgerald P.M.D., Axel M.G., Ostovic D., Anderson P.S., Huff J.R. J. Med. Chem. 37:1994;3443.
14. Kalish V., Kaldor S., Shetty B., Tatlock J., Davies J., Hammond M., Dressman B., Fritz J., Appelt K., Reich S., Musick L., Wu B.-W., Su K. Eur. J. Med. Chem. 30:1995;201s.
15. Reddy P., Ross J. Formulary. 34:1999;567.
16. Stoner E.J., Cooper A.J., Dickman D.A., Kolaczkowski L., Lallaman J.E., Liu J.-H., Oliver-Shaffer P.A., Patel K.M., Paterson J.J.B., Plata D.J., Riley D.A., Sham H.L., Stengel P.J., Tien J.-H. J. Org. Process Res. Devel. 4:2000;264.
17. Turner S.R. Curr. Med. Chem. 1:2002;141.
18. Rusconi S., La S. Catmancio S. Exp. Opin. Invest. Drugs. 11:2002;387.
19. Ghosh A.K., Fidanze S., Senanayake C.H. Synthesis. 1998;937.
20. Alterman M., Björsne M., Mühlman A., Classon B., Kvarnström I., Danielsson H., Markgren P.-O., Nillroth U., Unge T., Hallberg A., Samuelsson B. J. Med. Chem. 41:1998;3782.
21. Oscarsson K., Classon B., Kvarnström I., Hallberg A., Samuelsson B. Can. J. Chem. 78:2000;829.
22. Kempf D.J. Perspect. Drug Discov. Design. 2:1994;427.
23. Gosh A.K., Kincaid J.F., Cho W., Walters D.E., Krishnan K., Hussain K.A., Koo Y., Cho H., Rudall C., Holland L., Buthod J. Bioorg. Med. Chem. Lett. 8:1998;687.
24. Bolon P.J., Sells T.B., Nuesca Z.M., Purdy D.F., Nair V. Tetrahedron. 50:1994;7747.
25. Ozols A.M., Azhayev A.V., Dyatkina N.B., Krayevsky A.A. Synthesis. 1980;557.
26. Ewing G.J., Robins M.J. Org. Lett. 1:1999;635.
27. Mitsunobu O. Synthesis. 1981;1.
28. Zemplén G., Pascu E. Ber. Dtsch. Chem. Ges. 62:1929;534.
29. Williamson W. Justus Liebigs Ann. Chem. 77:1851;37.
30. Giuliano R.M. J. Org. Chem. 60:1995;202.
31. Wolfram M.L., Hanessian S. J. Org. Chem. 27:1962;1800.
32. Andersson, H. O.; Fridborga, K.; Löwgren, S.; Alterman, M.; Mühlman, A.; Björsne, M.; Gargb, N.; Kvarnström, I.; Schaalb, W.; Classon, B.; Karlén, A.; Danielsson, U. H.; Ahlséne, G.; Nillrothe, U.; Vrang, L.; Öberg, N.; Samuelsson, B.; Hallberg, A.; Unge, T. Manuscript in preparation.
33. Guex N., Peitsch M.C. Electrophoresis. 18:1997;2714.
34. Young, C. The Ray tracer POV-Ray 3.1 in Indianapolis, 1999.
35. Markgren, P.-O.; Lindgren, M.; Nillroth, U.; Danielson, U. H. In Aspartic Proteinases; Plenum Press: New York, 1998; pp 99-103.
36. Nillroth U., Vrang L., Markgren P.-O., Hultén J., Hallberg A., Danielson H.U. Antimicrob. Agents Chemother. 41:1997;2383.
37. Weislow O.S., Kiser R., Fine D.L., Bader J., Shoemaker R.H., Boyd M.R. Can. J. Chem. 81:1989;577.